New developments in diabetes happen slowly, yet at this year’s annual American Diabetes Association 77th Scientific Sessions there were many glimmers of hope, particularly in the area of new technologies and medications.
Oral, faster, smarter and all-around better insulins were discussed and positive data came out on the safety of the long acting insulin known as degludec (Tresiba) in the DEVOTE Trial.
The biggest news was on the cardiovascular benefits of a medication known as canagliflozin (Invokana) which showed benefit in terms of reducing heart disease risk. This supports the previous findings for empagliflozin (Jardiance) suggesting that all the medications in this class known as “SGLT-2 inhibitors” may have cardiovascular benefit.
Dr. Peters presented on four topics; updating the diabetes guidelines, continuous glucose monitoring safety, the new diabetes medication known as sotagliflozin (for people with both type 1 and type 2 diabetes) and the restrictive nature of current CMS rules regarding insulin pump therapy. Reporting for Medscape, Mark covered the news from the ADA and his videos can be found on-line.
Our WCD team, led by Dr. Peters, is grateful to be able to play a role in the process of advancing treatment for diabetes. We remain hopeful to develop new methods of care and establish higher levels of education for this underrepresented, life-threatening condition.